Reimbursement Request Information

OMNI®
SURGICAL SYSTEM

Target three points of resistance
with one intelligent device
Eye picture

ONLY OMNI CAN

The OMNI® Surgical System from Sight Sciences is the first and only glaucoma device indicated for canaloplasty followed by trabeculotomy for patients with primary open-angle glaucoma that allows you to:
PERFORM
Two implant-free procedures in both standalone MIGS and combo cataract
TARGET
Three points of resistance intended to lower IOP*
DELIVER
Sustained long-term IOP reduction1
RELY
On an established reimbursement code
*Trabecular meshwork (trabeculotomy), Schlemm’s canal (canaloplasty), and collector channels (canaloplasty).
1 Klabe K, et al. 2021 Jul 20. Clin Ophthalmol. 15:3121-3129.
Advancement has never
felt so good
Experience the Ergo-Series of the OMNI® Surgical System
OMNI Surgical System
Watch Video

KEY FEATURES OF THE ERGO-SERIES

News and Events
October 1-3
Join Sight Sciences at AAO 2022 in Chicago on October 1-3

Learn more by visiting: http://www.sightsciences.com/aao

March 9, 2023
Sight Sciences Launches the Ergo-Series of the OMNI® Surgical System

PDF Version
Ergo-Series of the OMNI® Surgical System by Sight Sciences, Inc.

Ergo-Series of the OMNI® Surgical System by Sight Sciences, Inc.

Read More
September 30, 2022
Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology Annual Meeting

MENLO PARK, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), today announced that 12 ophthalmic physicians will present their first-hand experience using the OMNI Surgical System as a standalone minimally invasive glaucoma surgery (MIGS) during this year’s annual AAO convention at McCormick Place in Chicago, IL. Meeting delegates are invited to attend the four sessions throughout the weekend at the Sight Sciences booth (#4843) to learn more about OMNI standalone treatment and engage directly with the panelists. Additionally, the soon to be released Ergo-Series of the OMNI Surgical System and the recently launched SION Surgical Instrument will be showcased at AAO 2022 and available for hands-on demos at the booth.

Read More
GET TO KNOW THE ERGO-SERIES TODAY

    State

    Important Product Information

    OMNI® Surgical System IMPORTANT PRODUCT INFORMATION
    Indications for Use

    The OMNI® Surgical System is indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm’s canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma.

    Contraindications

    Do not use the OMNI® in any situations where the iridocorneal angle is compromised or has been damaged (e.g., from trauma or surgery), since it may not be possible to visualize the angle or to properly pass the microcatheter.

    Do not use the OMNI® in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris.

    Do not use the OMNI® Surgical System in quadrants with previous MIGS implants.

    Please refer to the full Instructions for Use, available HERE, for warnings, precautions, and adverse event information.

    Warnings

    1. Do not use in cases where there is insufficient visibility to properly see the iridocorneal angle. The following conditions may prohibit sufficient visualization required for safe and successful cannula and microcatheter placement: corneal edema, corneal haze, corneal opacity, or any other conditions that may inhibit gonioscopic view of the iridocorneal angle and intended cannula entry location.

    2. Perform gonioscopy prior to taking a patient to surgery to exclude congenital anomalies of the iridocorneal angle, anterior segment dysgeneses, peripheral anterior synechiae (PAS), rubeosis, and any other angle abnormalities that could lead to improper placement of the cannula and microcatheter and pose a hazard.

    3. Maintain direct microscopic or gonioscopic visualization of the cannula tip and microcatheter tip at all times during the procedure to facilitate advancement and to avoid inadvertently damaging intraocular structures, kinking the microcatheter or unintended tearing of trabecular meshwork.

    4. The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. If intraocular pressure is not adequately maintained after surgery, the surgeon should initiate appropriate management of intraocular pressure.

    Potential adverse events

    Adverse events that may be reasonably associated with the use of the OMNI® System in the eye include, but are not limited to, the following: anterior chamber shallowing, severe, prolonged, or persistent intraocular inflammation, endophthalmitis or other ocular infection, aqueous misdirection, Descemet’s membrane tear or detachment, intracorneal hematoma, choroidal effusion, suprachoroidal hemorrhage, corneal decompensation, corneal injury, corneal edema or opacification, unintended trabeculotomy, cyclodialysis cleft, hyphema, hypopyon, hypotony, hypotony maculopathy, IOL dislocation, cataract formation, iris injury, tear, or iridodialysis, loss of vitreous, perforation of sclera, posterior capsular bag rupture, proliferative vitreoretinopathy, pupillary block, pupillary membrane formation, retinal detachment, retinal dialysis, retinal flap tears, secondary surgical intervention, including, but not limited to, glaucoma surgery, and vitreous hemorrhage. Federal (USA) law restricts this device to sale, distribution, or use by or on the order of a physician.

    Thank you for message

    We appreciate your interest in the OMNI Surgical System. A member of our team will review your inquiry and get back to you as soon as possible during business hours.

    Thank you for your interest in the OMNI® Surgical System.
    A member of our team will follow up with you shortly.